- Insulet Corp said on Tuesday Wayde McMillan would step down as the medical device maker's chief financial officer, effective Oct. 20, to join 3M's healthcare business.
The company expects full-year revenue growth of 22% to 25%, compared with its previous forecast of 18% to 22% growth. It sees total sales growth of its insulin delivery devices, Omnipod, to be at 25% to 28%, compared with its previous projection of 21% to 25% rise.I wouldn’t be surprised if ENB stock even doubles in value in the next 10 years. Here why. The post Where Will Enbridge Stock Be in 10 Years? appeared first on The Motley Fool Canada.
Billionaire investor Bill Ackman says he would be 'absolutely' interested in a deal with Elon Musk's X
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: